

BLONDER TONGUE LABORATORIES INC
 Form 4
 April 05, 2017

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Dietz Charles E

(Last) (First) (Middle)

C/O BLONDER TONGUE LABORATORIES, INC., ONE JAKE BROWN ROAD

(Street)

OLD BRIDGE, NJ 08857

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 BLONDER TONGUE LABORATORIES INC [BDR]

3. Date of Earliest Transaction (Month/Day/Year)
 04/04/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock, par value \$0.001	04/04/2017		A ⁽¹⁾	10,000	A \$ 0	191,086	D
Common Stock, par value \$0.001	04/04/2017		A ⁽²⁾	19,182	A \$ 0.55	210,268	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy) ⁽³⁾	\$ 0.55 ⁽⁴⁾	04/04/2017		A	10,000	⁽⁵⁾ 04/04/2027	Common Stock par value \$0.001	10,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Dietz Charles E
C/O BLONDER TONGUE LABORATORIES, INC.
ONE JAKE BROWN ROAD
OLD BRIDGE, NJ 08857

X

Signatures

/s/ Charles E.
Dietz

04/05/2017

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant of stock award under 2016 Director Equity Incentive Plan.
Pursuant to the company's Amended and Restated Director Stock Purchase Plan, the reporting person has elected to receive a fully vested stock award for shares of the company's common stock in lieu of cash payment of director fees otherwise payable to the reporting person.
- (2) The number of shares of common stock awarded represents the quotient of (i) the director fees payable to the reporting person divided by (ii) \$0.55, representing the average of the high and low trading prices reported on the NYSE MKT on April 4, 2017.
- (3) The stock option was granted under the 2016 Director Equity Incentive Plan.

Edgar Filing: BLONDER TONGUE LABORATORIES INC - Form 4

- (4) The exercise price equals the fair market value (equal to the average of the high and low selling prices as reported on the NYSE MKT) of the common stock on the grant date.
- (5) The stock option vests on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.